A final FDA rule and parallel NIH investments aim to make non-animal methods acceptable for regulatory safety data while preserving the option to use animal studies when needed.
The FDA issued a direct final rule to replace references to "animal" tests or studies with "nonclinical," effective Feb. 4, 2027, to explicitly allow non-animal methods where appropriate.
The NIH announced more than $88 million for biomedical infrastructure plus targeted programs — including a $7 million quantum challenge and a new NIH lab in Bethesda — to scale human-based testing approaches.
The change follows prior legislation (FDA Modernization Act 2.0) and ongoing implementation work (FDA Modernization Act 3.0) to broaden acceptable preclinical methods to include human-biology-based assays and NAMs.
# What changed
On Sept. 21 the FDA published a direct final rule that replaces references to "animal" tests or studies with the term "nonclinical" in drug safety regulations. The rule is scheduled to take effect Feb. 4, 2027. The agency says the change clarifies that non-animal methods can be used where appropriate to generate safety information for human drugs and biological products.
# Why this matters now
The rule is part of a broader HHS push to reduce what it calls "unnecessary animal testing" and to move toward human-biology-centered methods. That movement builds on the FDA Modernization Act 2.0, signed into law Dec. 29, 2022, which authorized use of "nonanimal or human biology-based test methods" such as cell-based assays, microphysiological systems, bioprinted models, or computer models. Congress later advanced FDA Modernization Act 3.0 to direct regulators to update rules to implement these options.
# What the FDA says the rule will do
# NIH actions running alongside the FDA rule
The NIH announced five programs to build infrastructure for human-based research. Concrete items announced include:
HHS Secretary Robert F. Kennedy Jr. framed the measures as modernizing regulations, investing in human-based technologies, and reducing dependence on animal models when better tools are available.
# How this fits into recent regulatory developments
# What stakeholders should watch next
# Bottom line
The administrative change — replacing "animal" with "nonclinical" — clarifies that regulators recognize a wider range of preclinical methods. The FDA says it does not ban animal studies or alter evidentiary thresholds. The NIH funding and programs are intended to help develop and scale human-relevant testing approaches so those options become practical and accessible for research and regulatory uses.
Through global collaboration, PETA scientists are advancing a non-animal method to study how inhaled chemicals affect human lungs. The post PETA Scientists Help Breathe New Life into Non-Animal Toxicity Testing appeared first on PETA .
As regulators expand the use of human-relevant testing approaches, companies face a more complex question: which methods are fit for purpose and capable of supporting defensible regulatory and risk-management decisions? CHICAGO, Sept. 13, 2026 /PRNewswire-PRWeb/ -- In June 2026, the U.S....
Scientists can now get more accurate safety data by testing drugs on organ-on-a-chip devices and organoids, meaning that there's increasingly less need to harm animals
Pilot study done by PETA Science Consortium International, US Environmental Protection Agency, & Belgium’s Flemish Institute for Technological Research
Recent progress on alternatives to animal testing is hugely welcome. But talk of "phasing out" animal research completely is misleading and could even be dangerous to scientists
High in the Western Himalayas, where villages cling to terraced slopes and livestock are the backbone of household survival, tribal communities have spent generations treating sick animals with remedies gathered from the surrounding forests. A new study published in Plant Biosystems by Niharika Sharma and Radha of Shoo
Loading more related stories...
Open the app view to save this story, compare related coverage, and continue from the same source.